Dashboard
Portfolios
Watchlist
Community
Discover
Screener
Narratives
Your Valuation
🌎 Global
Global
United States
Australia
United Kingdom
Canada
India
China
Argentina
Austria
Bahrain
Bangladesh
Belgium
Bermuda
Botswana
Brazil
Bulgaria
Chile
Colombia
Croatia
Cyprus
Czech Republic
Denmark
Egypt
Estonia
Finland
France
Germany
Ghana
Greece
Hong Kong
Hungary
Iceland
Indonesia
Ireland
Israel
Italy
Ivory Coast
Jamaica
Japan
Jordan
Kenya
Kuwait
Latvia
Lithuania
Luxembourg
Malawi
Malaysia
Malta
Mauritius
Mexico
Morocco
Namibia
Netherlands
New Zealand
Nigeria
Norway
Oman
Pakistan
Palestinian Authority
Peru
Philippines
Poland
Portugal
Qatar
Romania
Russia
Saudi Arabia
Serbia
Singapore
Slovakia
Slovenia
South Africa
South Korea
Spain
Sri Lanka
Sweden
Switzerland
Taiwan
Tanzania
Thailand
Trinidad & Tobago
Tunisia
Turkey
Uganda
Ukraine
United Arab Emirates
Venezuela
Vietnam
Zambia
Zimbabwe
Create a narrative
Global Community
Our community narratives are driven by numbers and valuation.
Create a narrative
Community Investing Ideas
Global Weekly Picks
Airbnb
TI
TickerTickle
Community Contributor
Airbnb (ABNB): Still one of the most interesting bets in travel
Key insights Airbnb is changing from a travel-only app to a full lifestyle platform (stays, rentals, experiences) International markets are growing faster than the US, which is slowing down Product experience is improving a lot, with AI making search and booking easier Regulations are becoming a big risk, especially in Europe where listings are getting removed The way people move around the world has changed. It’s not only about holidays anymore.
View narrative
US$163.75
FV
23.6% undervalued
intrinsic discount
12.00%
Revenue growth p.a.
Set Fair Value
11
users have liked this narrative
6
users have commented on this narrative
46
users have followed this narrative
New
narrative
ING Groep
PI
PittTheYounger
Community Contributor
ING leads the pack when it comes to pivoting towards non-lending income
ING, of course, is a bank; and banks don't like falling interest rates, right? For the dominant stream of income is their core business model, i.e. borrowing short-term and lending long-term, reaping the difference in interest rates in the process.
View narrative
€27.92
FV
23.7% undervalued
intrinsic discount
9.00%
Revenue growth p.a.
Set Fair Value
6
users have liked this narrative
0
users have commented on this narrative
17
users have followed this narrative
New
narrative
Coles Group
RO
Robbo
Community Contributor
Coles (ASX: COL): Safe, Steady, and Surprisingly Cheap
The supermarket chain Coles is the kind of “boring” business that may have been overlooked as an investment opportunity. Although it was divested from Wesfarmers in 2018, Coles’ heritage traces back to 1914 — giving it over 110 years of history.
View narrative
AU$22.00
FV
4.3% undervalued
intrinsic discount
8.72%
Revenue growth p.a.
Set Fair Value
5
users have liked this narrative
2
users have commented on this narrative
17
users have followed this narrative
New
narrative
All companies
Popular
Undervalued
Overvalued
Load previous narratives
Delek US Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 12 Analysts
Enterprise Optimization And Midstream Investment Will Strengthen US Refining
Key Takeaways Ongoing operational optimization and infrastructure investments are expected to boost margins, lower costs, and create new earnings streams. Strong industry demand and disciplined capital allocation position the company for enhanced cash flow, shareholder returns, and financial flexibility.
View narrative
US$22.17
FV
1.8% undervalued
intrinsic discount
-1.49%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
5
users have followed this narrative
3 days ago
author updated this narrative
Ocular Therapeutix
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Future Drug Approvals Will Expand Retinal Disease Treatments
Key Takeaways Potential market leadership in ophthalmology driven by innovative product launches, data differentiation, and expansion into new high-burden eye disease indications. Accelerated commercialization, diversified revenue streams, and strong financial position provide room for growth and protect against immediate dilution risks.
View narrative
US$17.45
FV
27.7% undervalued
intrinsic discount
50.44%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
3 days ago
author updated this narrative
Olo
AN
AnalystConsensusTarget
Consensus Narrative from 4 Analysts
FreedomPay Integration Will Expand Card Present Solutions
Key Takeaways Expanding Olo Pay with improved card-present processing and leveraging FreedomPay partnership aims to boost revenue growth and enhance gross profit through better payment processing. Strategy focuses on increasing brand adoption of Order, Pay, and Engage suites to drive ARPU growth, improve margins, and enhance profitability with efficient data use.
View narrative
US$10.25
FV
0.4% undervalued
intrinsic discount
17.95%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
8
users have followed this narrative
3 days ago
author updated this narrative
Altice USA
AN
AnalystConsensusTarget
Consensus Narrative from 15 Analysts
Fiber Upgrades And Bundling Will Unlock Future Broadband Opportunities
Key Takeaways Expansion of fiber network and bundling of broadband, mobile, and value-added services are strengthening customer loyalty and driving revenue growth. Operational efficiencies, digitalization, and capital structure improvements are boosting margins, cash flow, and financial flexibility for future investments.
View narrative
US$2.78
FV
14.9% undervalued
intrinsic discount
-2.19%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
3
users have followed this narrative
3 days ago
author updated this narrative
Arcus Biosciences
AN
AnalystConsensusTarget
Consensus Narrative from 11 Analysts
Phase 3 Trials Will Shape Casdatifan Prospects Despite Regulatory Hurdles
Key Takeaways Arcus Biosciences is focusing on casdatifan's late-stage development, promising significant differentiation and competitive advantage in the RCC market. Strong financial partnerships and a long cash runway ensure sustained R&D investment and potential earnings growth through strategic planning.
View narrative
US$28.36
FV
63.4% undervalued
intrinsic discount
7.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
10
users have followed this narrative
3 days ago
author updated this narrative
Elme Communities
AN
AnalystConsensusTarget
Consensus Narrative from 3 Analysts
Robust Multifamily Trends Will Boost Future Asset Sales
Key Takeaways Strong rental demand, tight supply, and strategic market focus drive high occupancy, robust leasing, and support premium asset valuations in core regions. Operational efficiencies and successful management of policy challenges enhance asset appeal, attract investor interest, and boost distributable proceeds for shareholders.
View narrative
US$18.33
FV
9.0% undervalued
intrinsic discount
0.65%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
0
users have followed this narrative
3 days ago
author updated this narrative
Immunocore Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 15 Analysts
Aging Demographics And Late-Stage Trials Will Expand Global Markets
Key Takeaways Expanding therapeutic portfolio and successful market entry reduce reliance on a single product and support a foundation for future revenue growth. Strong pricing power, effective cost management, and increased payer reimbursement position the company for stable margins and operational flexibility.
View narrative
US$62.00
FV
47.0% undervalued
intrinsic discount
15.68%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
7
users have followed this narrative
3 days ago
author updated this narrative
SHCO
Soho House & Co
AN
AnalystConsensusTarget
Consensus Narrative from 1 Analyst
Global Expansion And Operational Improvements Will Drive Future Performance
Key Takeaways Consistent membership growth and new house openings are expected to drive future revenue increases for Soho House & Co. Operational and strategic enhancements, including ERP systems and premium memberships, aim to boost profitability and improve net margins. Financial misstatements and strategic uncertainty may undermine investor confidence, impact strategic decisions, and pose risks to stable future revenue growth.
View narrative
US$9.00
FV
15.1% undervalued
intrinsic discount
7.62%
Revenue growth p.a.
Set Fair Value
0
users have liked this narrative
0
users have commented on this narrative
1
users have followed this narrative
3 days ago
author updated this narrative
AMC Entertainment Holdings
AN
AnalystConsensusTarget
Consensus Narrative from 5 Analysts
Premium Cinema Experiences And Urban Venues Will Redefine Entertainment
Key Takeaways Premium formats, diversified content, and loyalty programs attract new audiences, boost ticket and concession sales, and drive stable, incremental revenue. Portfolio optimization, debt reduction, and strong cash management strengthen profitability, operational efficiency, and capacity for reinvestment.
View narrative
US$3.32
FV
9.6% undervalued
intrinsic discount
5.00%
Revenue growth p.a.
Set Fair Value
1
users have liked this narrative
0
users have commented on this narrative
27
users have followed this narrative
3 days ago
author updated this narrative
Value any company in seconds
Popular companies